Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Jun 04 | 2022ADA 2022 Key Press Releases (June 4)Purchase Blast$599
Posted in: Basal Insulin, Glucose Monitoring, Other Jun 03 | 2022ADA 2022 Key Press Releases (June 3)Purchase Blast
$599
Posted in: Basal Insulin, Other Jun 01 | 2022First Cagrisema Pivotal Trial on CT.gov; Lannett Doses 50% of Patients in Bs-glargine Pivotal TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i May 31 | 2022Abbott Announces Libre 3 Clearance; Lexicon Resubmits Sota NDA; Dexcom Denies Insulet Acquisition SpeculationPurchase Blast
$599
Posted in: Glucose Monitoring, Other May 26 | 2022Bigfoot Hires Matt Rainville as CCO; Medtronic CY Q1 ’22 (FY Q4 ’22) Earnings Update; Pfizer’s NASH Combo Receives Fast Track Designation; ReShape and OpenLoop Collaboration for Virtual Weight Loss Coaching ProgramPurchase Blast
$599
Posted in: GLP-1RA + Basal, Other May 25 | 2022Bayer Presents New Finerenone Analysis; Lilly to Invest $2.1B in Additional Manufacturing Capacity; Oramed Granted Combination Therapy Patent for Oral GLP-1+InsulinPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 24 | 2022Mounjaro WAC Pricing Analysis; Lilly @ UBS 2022Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other May 19 | 2022Provention Hosts Teplizumab Commercial Launch Investor Event; Lifescan Initiates New RWE Study; Diamyd Enrolls First Patient in Ph3 T1DM Vaccine Trial; Dario Announces New Employer and Provider Contracts; MySugarWatch Expands DTC Marketing Campaign; Adocia Q1 ’22 Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 18 | 2022Mounjaro (tirzepatide) Label and Website AnalysisPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, SGLT2i May 17 | 2022MannKind to Acquire Zealand’s V-Go T2DM Patch Pump; Sernova/Evotec Collaboration for Beta Cell Therapy; AACE Updates NAFLD GuidelinesPurchase Blast
$599
Posted in: Other May 16 | 2022May 16-19 CHMP Agenda; Glyscend Therapeutics Completes Ph1 GLY-200 Trial in T2DMPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other May 16 | 2022Movano and Embecta Q1 ’22 Earnings Updates; Hygieia Launches d-Nav Clinical Partnership Program in MichiganPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 13 | 2022Tirzepatide Approved in US as "Mounjaro"Purchase Blast
$599
Posted in: Insulin Delivery, Other May 12 | 2022Zealand and Dario Q1 ’22 Earnings Updates; NexImmune, Yale, and JDRF research collaboration for T1DMPurchase Blast
$599
Posted in: Glucagon, Other May 11 | 2022Novo Highlights CV Risks of Diabetes in Unbranded Campaign Featuring Anthony Anderson; Xeris Q1 ’22 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Other May 10 | 2022Senseonics, Viatris, and Bayer Q1 ’22 Earnings Updates; Novo and Flagship Pioneering Collaboration; First Patient Dosed in Adocia Ph3 BC Lispro TrialPurchase Blast
$599
Posted in: Bolus Insulin, Insulin Delivery, Other May 06 | 2022Insulet, Vertex, MannKind, and Intercept Q1 ‘22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, SGLT2i May 05 | 2022Novo Q1 '22 London Earnings; Lilly Initiates Second Trial in Ph3 QWINT Program; Ionis, Provention Bio, Lexicon, and Lannett Q1 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Insulin Delivery, Other May 05 | 2022Tandem, Amarin, and Regeneron Q1 ’22 Earnings UpdatesPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
